Picture of GSK logo

GSK GSK News Story

0.000.00%
gb flag iconLast trade - 00:00
HealthcareConservativeLarge CapHigh Flyer

REG - GSK PLC - Director/PDMR Shareholding

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240326:nRSZ3417Ia&default-theme=true

RNS Number : 3417I  GSK PLC  26 March 2024

GSK plc (the 'Company')

Transaction notification

 1.  Details of PDMR/person closely associated with them ('PCA')
 a)  Name                                     Sally Jackson
 b)  Position/status                          SVP, Global Communications & CEO Office
 c)  Initial notification/                    Initial notification

     amendment
 2.  Details of the issuer, emission allowance market participant, auction
     platform, auctioneer or auction monitor
 a)  Name                                     GSK plc
 b)  LEI                                      5493000HZTVUYLO1D793
 3.  Details of the transaction(s): section to be repeated for (i) each type of
     instrument; (ii) each type of transaction; (iii) each date; and (iv) each
     place where transaction(s) has been conducted
 a)  Description of the financial instrument  Ordinary shares of 31 ¼ pence each ('Ordinary Shares')

                                              ISIN: GB0009252882

 b)  Nature of the transaction                The sale of 3,551 Ordinary Shares
 c)  Price(s) and volume(s)                   Price(s)   Volume(s)
                                              £16.8719   3,551

 

 d)  Aggregated information                   N/A (single transaction)

     Aggregated volume Price

 e)  Date of the transaction                  2024-03-25
 f)  Place of the transaction                 London Stock Exchange (XLON)

 

 

 

d)

Aggregated information

Aggregated volume Price

N/A (single transaction)

 

 

 

 

 

 

e)

Date of the transaction

2024-03-25

f)

Place of the transaction

 

London Stock Exchange (XLON)

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  DSHSEEFSMELSELD

Recent news on GSK

See all news